Yifan Biologics Records Five Block Trades Totaling ¥49.21 Million on July 15, Institutional Buying Dominates at ¥46.77 Million with 12.99% Discount

Market Watcher07-16

Yifan Biologics (688382.SH) surged 7.89% to close at ¥38.95 on July 15, while simultaneously registering five block trades totaling 1.452 million shares worth ¥49.2083 million. Notably, all transactions occurred at a uniform price of ¥33.89 per share, representing a significant 12.99% discount to the day's closing price.

Institutional investors dominated the buying activity, accounting for four transactions worth ¥46.77 million combined. These institutional purchases were executed through specialized institutional trading seats, with China International Capital Corporation (CICC) Shanghai Branch serving as the exclusive seller. The trades comprised: - A ¥25.4175 million transaction for 750,000 shares - A ¥10.167 million transaction for 300,000 shares - A ¥8.4725 million transaction for 250,000 shares - A ¥2.7112 million transaction for 80,000 shares

The remaining transaction, valued at ¥2.4401 million for 72,000 shares, was facilitated by J.P. Morgan Securities (China) Company Limited Shanghai Yincheng Road Branch as the buyer.

This activity continues a trend of substantial block trading for Yifan Biologics, with 34 such transactions totaling ¥183 million occurring over the past three months. Despite recent gains—the stock has risen 24.72% over the last five trading sessions—main funds recorded a net outflow of ¥4.6787 million during this period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment